Article
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer.
Cancer cell - 13 Apr 2020
Alam Hunain, Tang Ming, Maitituoheti Mayinuer, Dhar Shilpa S, Kumar Manish, Han Chae Young, Ambati Chandrashekar R, Amin Samir B, Gu Bingnan, Chen Tsai-Yu, Lin Yu-Hsi, Chen Jichao, Muller Florian L, Putluri Nagireddy, Flores Elsa R, DeMayo Francesco J, Baseler Laura, Rai Kunal, Lee Min Gyu
Abstract excerpt
Epigenetic modifiers frequently harbor loss-of-function mutations in lung cancer, but their tumor-suppressive roles are poorly characterized. Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer. Here, we show that lung-specific loss of Kmt2d promotes lung tumorigenesis in mice and upregulates pro-tumorigenic programs,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.